Factors predicting the early biochemical response to [177Lu]Lu-PSMA therapy in patients with metastatic castration resistant prostate cancer

Document Type : Original Article

Authors

1 Research Center for Nuclear Medicine, Tehran University of Medical Sciences, Tehran, Iran

2 Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

3 Khatam PET/CT Center, Khatam Al-Anbia Hospital, Tehran, Iran

Abstract

Introduction: Targeted radionuclide therapy with [177Lu]Lu-prostate-specific membrane antigen (PSMA) has shown promising results for the treatment of castration-resistant prostate cancer (mCRPC). Nevertheless, a proportion of patients do not respond to this therapy. Here, we aimed to evaluate the prognostic significance of the pretreatment pathologic and laboratory factors for the prediction of biochemical response to the first cycle of [177Lu]Lu-PSMA therapy.
Methods: In this retrospective study, mCRPC patients, referred for [177Lu]Lu-PSMA therapy, were included. We retrieved the data of patients, undergone [177Lu]Lu-PSMA, from March 2019 to March 2021. Multiple baseline pathologic and laboratory parameters were extracted and correlated with the response to the first cycle. The prostate-specific antigen (PSA) level was evaluated six weeks after [177Lu]Lu-PSMA therapy for the biochemical response.
Results: Forty-three patients with a mean age of 69.8±10.2 were included. Bone and visceral metastases were present in 81.4% and 14.0% of the patients, respectively. Except for two, all patients had received hormone- and chemotherapy. The mean PSA level was 189.9±259.0 at baseline. Following one cycle of [177Lu]Lu-PSMA, “≥ 10% PSA response” and “≥ 50% PSA response” were seen in 81.4% and 44.2% of the patients, respectively. Patients with higher baseline PSA more frequently had ≥ 10% PSA response (p= 0.004). Also, the reduction in the PSA level correlated with baseline PSA (p=0.013, r=0.375).
Conclusion: [177Lu]Lu-PSMA therapy results in the biochemical response in a considerable number of patients after one cycle. In nearly half of patients, PSA declines more than 50%. Higher baseline PSA is correlated with the level of PSA response.

Keywords

Main Subjects

References

  1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021 May;71(3):209-49.
  2. Kirby M, Hirst C, Crawford ED. Characterizing the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract. 2011 Nov;65(11):1180-92.
  3. Barber TW, Singh A, Kulkarni HR, Niepsch K, Billah B, Baum RP. Clinical outcomes of (177)Lu-PSMA radioligand therapy in earlier and later phases of metastatic castration-resistant prostate cancer grouped by previous taxane chemotherapy. J Nucl Med. 2019 Jul;60(7):955-62.
  4. Puranik AD, Dromain C, Fleshner N, Sathekge M, Pavel M, Eberhardt N, Zengerling F, Marienfeld R, Grunert M, Prasad V. Target heterogeneity in oncology: the best predictor for differential response to radioligand therapy in neuroendocrine tumors and prostate cancer. Cancers (Basel). 2021 Jul 19;13(14):3607.
  5. Conteduca V, Mosca A, Brighi N, de Giorgi U, Rescigno P. New prognostic biomarkers in metastatic castration-resistant prostate cancer. Cells. 2021 Jan 19;10(1).
  6. Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, Tagawa ST, Nordquist LT, Vaishampayan N, El-Haddad G, Park CH, Beer TM, Armour A, Pérez-Contreras WJ, DeSilvio M, Kpamegan E, Gericke G, Messmann RA, Morris MJ, Krause BJ. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021 Sep 16;385(12):1091-1103.
  7. Manafi-Farid R, Harsini S, Saidi B, Ahmadzadehfar H, Herrmann K, Briganti A, Walz J, Beheshti M. Factors predicting biochemical response and survival benefits following radioligand therapy with [(177)Lu]Lu-PSMA in metastatic castrate-resistant prostate cancer: a review. Eur J Nucl Med Mol Imaging. 2021 Nov;48(12):4028-4041.
  8. Kim YJ, Kim YI. Therapeutic responses and survival effects of 177Lu-PSMA-617 radioligand therapy in metastatic castrate-resistant prostate cancer: A meta-analysis. Clin Nucl Med. 2018 Oct;43(10):728-34.
  9. Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, Antonarakis ES, Beer TM, Carducci MA, Chi KN, Corn PG, de Bono JS, Dreicer R, George DJ, Heath EI, Hussain M, Kelly WK, Liu G, Logothetis C, Nanus D, Stein MN, Rathkopf DE, Slovin SF, Ryan CJ, Sartor O, Small EJ, Smith MR, Sternberg CN, Taplin ME, Wilding G, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3. J Clin Oncol. 2016 Apr 20;34(12):1402-18.
  10. Ahmadzadehfar H, Eppard E, Kürpig S, Fimmers R, Yordanova A, Schlenkhoff CD, Gärtner F, Rogenhofer S, Essler M. Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer. Oncotarget. 2016 Mar 15;7(11):12477-88.
  11. Rahbar K, Bode A, Weckesser M, Avramovic N, Claesener M, Stegger L, Bögemann M. Radioligand Therapy With 177Lu-PSMA-617 as A Novel Therapeutic Option in Patients With Metastatic Castration Resistant Prostate Cancer. Clin Nucl Med. 2016 Jul;41(7):522-8.
  12. Seifert R, Kessel K, Schlack K, Weckesser M, Bögemann M, Rahbar K. Radioligand therapy using [(177)Lu]Lu-PSMA-617 in mCRPC: a pre-VISION single-center analysis. Eur J Nucl Med Mol Imaging. 2020 Aug;47(9):2106-2112.
  13. Rahbar K, Ahmadzadehfar H, Kratochwil C, Haberkorn U, Schäfers M, Essler M, Baum RP, Kulkarni HR, Schmidt M, Drzezga A, Bartenstein P, Pfestroff A, Luster M, Lützen U, Marx M, Prasad V, Brenner W, Heinzel A, Mottaghy FM, Ruf J, Meyer PT, Heuschkel M, Eveslage M, Bögemann M, Fendler WP, Krause BJ. German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med. 2017 Jan;58(1):85-90.
  14. Gafita A, Fendler WP, Hui W, Sandhu S, Weber M, Esfandiari R, Calais J, Rauscher I, Rathke H, Tauber R, Delpassand ES, Weber WA, Herrmann K, Czernin J, Eiber M, Hofman MS. Efficacy and safety of (177)Lu-labeled prostate-specific membrane antigen radionuclide treatment in patients with diffuse bone marrow involvement:A multicenter retrospective study. Eur Urol. 2020 Aug;78(2):148-54.
  15. Leibovici D, Spiess PE, Agarwal PK, Tu SM, Pettaway CA, Hitzhusen K, Millikan RE, Pisters LL. Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level. Cancer. 2007 Jan 15;109(2):198-204.
  16. Ahmadzadehfar H, Wegen S, Yordanova A, Fimmers R, Kürpig S, Eppard E, Wei X, Schlenkhoff C, Hauser S, Essler M. Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [(177)Lu]Lu-PSMA-617. Eur J Nucl Med Mol Imaging. 2017 Aug;44(9):1448-54.
  17. Soydal C, Araz M, Urun Y, Nak D, Ozkan E, Kucuk NO. Prognostic importance of PSA response in patients who received Lutetium-177 PSMA treatment for castration resistant prostate cancer. Q J Nucl Med Mol Imaging. 2021 Sep;65(3):282-286.
  18. Izumi K, Lin WJ, Miyamoto H, Huang CK, Maolake A, Kitagawa Y, Kadono Y, Konaka H, Mizokami A, Namiki M. Outcomes and predictive factors of prostate cancer patients with extremely high prostate-specific antigen level. J Cancer Res Clin Oncol. 2014 Aug;140(8):1413-9.
  19. Matsubara N, Chi KN, Özgüroğlu M, Rodriguez-Antolin A, Feyerabend S, Fein L, Alekseev BY, Sulur G, Protheroe A, Li S, Mundle S, De Porre P, Tran N, Fizazi K. Correlation of prostate-specific antigen kinetics with overall survival and radiological progression-free survival in metastatic castration-sensitive prostate cancer treated with abiraterone acetate plus prednisone or placebos added to androgen deprivation therapy: post hoc analysis of phase 3 LATITUDE study. Eur Urol. 2020 Apr;77(4):494-500.
  20. Viglialoro R, Esposito E, Zanca R, Gessi M, Depalo T, Aghakhanyan G, Bartoli F, Sollini M, Erba PA. What to trust, PSA or [(68)Ga]Ga-PSMA-11: Learn from experience. Res Rep Urol. 2021;13:597-601.

Files

Share

How to cite

Statistics